The role of SOCS2 in recombinant human growth hormone (rhGH) regulating lipid metabolism in high-fat-diet-induced obesity mice

Molecular Biology Reports

Volumn 40, Issue 3, 2013, Pages 2319-2326

  Yang, Hai Li ^a   Feng, Min ^a   Tan, Xiao ^a   Yan, Guo Yong ^a   Sun, Chao ^a  

^a NORTHWEST A F UNIVERSITY   (China)

Author keywords

Growth hormone; High fat diet; Lipid metabolism; Mice; SOCS2

Indexed keywords

FAS ANTIGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN GROWTH HORMONE; JANUS KINASE 2; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; STAT5 PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 2; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRIACYLGLYCEROL LIPASE;

ADIPOGENESIS; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; FAS GENE; FAT CONTENT; FAT MASS; GENE; INTRAABDOMINAL FAT; LIPID DIET; LIPID METABOLISM; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SOCS1 GENE; SOCS2 GENE; SOCS3 GENE; SREBP 1C GENE; SUBCUTANEOUS FAT; WEIGHT REDUCTION;

ADIPOSE TISSUE; ANIMALS; BODY WEIGHT; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; HUMAN GROWTH HORMONE; HUMANS; JANUS KINASE 2; LIPASE; LIPID METABOLISM; LIPIDS; LIVER; MALE; MICE; OBESITY; ORGAN SIZE; ORGAN SPECIFICITY; PHOSPHORYLATION; STAT5 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

MUS;

EID: 84878378861     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-012-2313-5     Document Type: Article

References (16)

1. Lichanska AM, Waters MJ (2008) How growth hormone controls growth, obesity and sexual dimorphism. Trends Genet 24(1):41-47
2. Krebs DL, Hilton DJ (2001) SOCS proteins: negative regulators of cytokine signaling. Stem Cells 19(5):378-387
3. Nicola NA, Greenhalgh CJ (2000) The suppressors of cytokine signaling (SOCS) proteins: important feedback inhibitors of cytokine action. Exp Hematol 28(10):1105-1112
4. Gylvin T et al (2009) Functional SOCS1 polymorphisms are associated with variation in obesity in whites. Diabetes Obes Metab 11(3):196-203
5. Sabio G et al (2008) A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 322(5907):1539-1543
6. Metcalf D et al (2000) Gigantism in mice lacking suppressor of cytokine signalling-2. Nature 405(6790):1069-1073
7. Tollet-Egnell P et al (1999) Growth hormone regulation of SOCS-2, SOCS-3, and CIS messenger ribonucleic acid expression in the rat. Endocrinology 140(8):3693-3704
8. Jorgensen JOL et al (2006) GH receptor signaling in skeletal muscle and adipose tissue in human subjects following exposure to an intravenous GH bolus. Am J Physiol Endocrinol Metab 291(5):E899-E905
9. Greenhalgh CJ et al (2002) Biological evidence that SOCS-2 can act either as an enhancer or suppressor of growth hormone signaling. J Biol Chem 277(43):40181-40184
10. Studzinski ALM et al (2009) SOCS1 and SOCS3 are the main negative modulators of the somatotrophic axis in liver of homozygous GH-transgenic zebrafish (Danio rerio). Gen Comp Endocrinol 161(1):67-72
11. Slingerland LI et al (2008) Growth hormone excess and the effect of octreotide in cats with diabetes mellitus. Domest Anim Endocrinol 35(4):352-361
12. Linlin Z, Xingjia Y, Hui W (2005) Study on change of GH/IGF-I axis in diet-induced male obese rats. China Public Health 21(3):269-270
13. Greenhalgh CJ et al (2002) Growth enhancement in suppressor of cytokine signaling 2 (SOCS-2)-deficient mice is dependent on signal transducer and activator of transcription 5b (STAT5b). Mol Endocrinol 16(6):1394-1406
14. Flores-Morales A et al (2006) Negative regulation of growth hormone receptor signaling. Mol Endocrinol 20(2):241-253
15. Greenhalgh CJ et al (2005) SOCS2 negatively regulates growth hormone action in vitro and in vivo. J Clin Investig 115(2):397-406
16. Karavitaki N, Botusan I, Radian S et al (2005) The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Clin Endocrinol 62(3):282-288